Cross-reactive epitopes on β2-glycoprotein-I and Saccharomyces cerevisiae in patients with the antiphospholipid syndrome

I. Krause, M. Blank, R. Cervera, J. Font, T. Matthias, S. Pfeiffer, I. Wies, A. Fraser, Y. Shoenfeld*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

Abstract

Anti-Saccharomyces cerevisiae antibodies (ASCA), directed against the phosphopeptidomannan (PPM) part of the cell wall of the yeast, have been identified as an important and specific serological marker for Crohn's disease. We evaluated the prevalence and properties of ASCA in APS patients. Thirty-one out of 155 APS patients tested positive for ASCA (20.0%), compared to 5.0% in healthy controls (P < 0.05). The presence of ASCA was not associated with any specific manifestation of APS. The ASCA found to be the population of anti-β2GPI antibodies (Abs). Affinity purified anti-β2GPI from ASCA-positive sera on a β2GPI column, bound specifically the PPM, as shownby direct binding and competition assays (95-98%). The PPM inhibited differentially the anti-β2GPI binding to β2GPI. Since the anti-β2GPI anti-PPM could bind only native form of β2GPI and not the recombinant form, we assume that these specific anti-β2GPI subpopulations of Abs are directed to the glycosylated site of the molecule. In conclusion, a subpopulation of anti-β2GPI is specific to the glycosylated site of the β2GPI molecule that cross-reacts with PPM.

Original languageEnglish
Title of host publicationAutoimmunity, Part D
Subtitle of host publicationAutoimmune Disease, Annus Mirabilis
PublisherBlackwell Publishing Inc.
Pages481-488
Number of pages8
ISBN (Print)157331708X, 9781573317085
DOIs
StatePublished - Jun 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1108
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

Keywords

  • Autoimmunity
  • Crohn's disease
  • Mannan
  • β2-glycoprotein-I

Fingerprint

Dive into the research topics of 'Cross-reactive epitopes on β2-glycoprotein-I and Saccharomyces cerevisiae in patients with the antiphospholipid syndrome'. Together they form a unique fingerprint.

Cite this